drugset / Trial / NCT05423977
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
An open-label, multicenter, phase I dose-escalation study to assess the safety, Pharmacokinetic (PK), immunogenicity and preliminary anti-tumor activity of ZV0203 in patients with HER2-Positive advanced solid tumors
Timeline
- Start
- 2021-12-17
- Primary completion
- 2023-05-05
- Completion
- 2026-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZV0203 | Unknown | 0.3 mg/kg | — |
| Subject | ZV0203 | Unknown | 0.6 mg/kg | — |
| Subject | ZV0203 | Unknown | 1.2 mg/kg | — |
| Subject | ZV0203 | Unknown | 1.8 mg/kg | — |
| Subject | ZV0203 | Unknown | 2.7 mg/kg | — |
| Subject | ZV0203 | Unknown | 3.6 mg/kg | — |
Indications
No indication recorded.